Ernexa Shares Jump After Independent Preclinical Validation of ERNA-101 in Ovarian Cancer Models
Ernexa Therapeutics stock climbed 30% after an independent contract research organization reproduced earlier preclinical findings showing complete tumor clearance and long-term survival in ovarian cancer models when ERNA-101 was given with anti-PD-1 therapy. The validation supports the company's timeline toward an Investigational New Drug submissio…